University of Hertfordshire

Orvinols with mixed kappa/Mu opioid receptor agonist activity

Research output: Contribution to journalArticlepeer-review

  • Benjamin M. Greedy
  • Faye Bradbury
  • Mark P. Thomas
  • Konstantinos Grivas
  • Gerta Cami-Kobeci
  • Ashley Archambeau
  • Kelly Bosse
  • Mary J. Clark
  • Mario Aceto
  • John W. Lewis
  • John R. Traynor
  • Stephen M. Husbands
View graph of relations
Original languageEnglish
Pages (from-to)3207-3216
Number of pages10
JournalJournal of Medicinal Chemistry
Early online date25 Feb 2013
Publication statusPublished - 25 Apr 2013


Dual-acting kappa opioid receptor (KOR) agonist and mu opioid receptor (MOR) partial agonist ligands have been put forward as potential treatment agents for cocaine and other psychostimulant abuse. Members of the orvinol series of ligands are known for their high binding affinity to both KOR and MOR, but efficacy at the individual receptors has not been thoroughly evaluated. In this study, it is shown that a predictive model for efficacy at KOR can be derived, with efficacy being controlled by the length of the group attached to C20 and by the introduction of branching into the side chain. In vivo evaluation of two ligands with the desired in vitro profile confirms both display KOR, and to a lesser extent MOR, activity in an analgesic assay suggesting that, in this series, in vitro measures of efficacy using the [35S]GTPγS assay are predictive of the in vivo profile.


© 2013 American Chemical Society

ID: 16761836